Provectus Pharmaceuticals, Inc. to Present at "2nd Annual Cancer Immunotherapy ... - MarketWatch (press release)

Provectus Pharmaceuticals, Inc. to Present at "2nd Annual Cancer Immunotherapy ... MarketWatch (press release) Its dermatological drug PH-10 too targets abnormal or pathologic cells, with the actual focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase ii trials of PV-10 As a therapy for pathological process melanoma, and of PH-10 as a topical ... and more » Link To Article